Alpha-galactosylceramides (a-GalCer) isolated form marine sponges can prevent liver metastases of cancer cells. This remarkable anti tumor effect of a-GalCer is mediated by NKT cells, a specialized set of T cells restricted by CD1d, a member of the lipid antigen-presenting CD1 family. Upon in vivo injection, a-GalCer stimulates NKT cells which rapidly induce a complex cascade of cellular activation involving NK cells, dendritic cells, B cells and T cells. Thus, through the NKT cells, its primary target, a-GalCer exhibits the properties of a glycolipid adjuvant with the potential to enhance or modify a brad range of immune responses. The long term goal is to understand the protective value of the CD1 system of antigen presentation. This application focuses on determining the cellular and molecular consequences of activation of the CD1/NKT pathway with a-GalCer, the ligand of NKT cells, and their potential applications in host defense against infections and tumors, and in autoimmunity.
The specific aims are 1- to characterize the cascade of activation events that follows NKT cell activation in vivo, by defining the respective contributions of the cell types, the surface receptors and the soluble mediators (cytokines and chemokines) that are sequentially induced; 2-to determine the consequences of of NKT cell activation on adaptive, antigen specific T and B cell responses, and dissect the adjuvant effects of a-GalCer on the individual components of these responses; 3- to determine the consequences of NKT cell activation during the course of autoimmune, infectious and tumoral conditions such as NOD mouse autoimmune diabetes, MCMV infection and liver metastases of melanoma. These studies offer an opportunity to dissect the molecular and cellular events involved in the adjuvant effect of a glycolipid molecule an may lead to clinical applications in the prevention and treatment of infectious, autoimmune and tumor conditions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA087060-03
Application #
6514630
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Mccarthy, Susan A
Project Start
2000-05-15
Project End
2002-08-31
Budget Start
2002-05-15
Budget End
2002-08-31
Support Year
3
Fiscal Year
2002
Total Cost
$96,220
Indirect Cost
Name
Princeton University
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
002484665
City
Princeton
State
NJ
Country
United States
Zip Code
08544
Park, Se-Ho; Kyin, Tim; Bendelac, Albert et al. (2003) The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol 170:1197-201
Cantu 3rd, Carlos; Benlagha, Kamel; Savage, Paul B et al. (2003) The paradox of immune molecular recognition of alpha-galactosylceramide: low affinity, low specificity for CD1d, high affinity for alpha beta TCRs. J Immunol 170:4673-82
Benlagha, Kamel; Kyin, Tim; Beavis, Andrew et al. (2002) A thymic precursor to the NK T cell lineage. Science 296:553-5
Procopio, Daniela O; Almeida, Igor C; Torrecilhas, Ana Claudia T et al. (2002) Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway. J Immunol 169:3926-33
Park, S H; Weiss, A; Benlagha, K et al. (2001) The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med 193:893-904